Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With <i>METamp</i> After Osimertinib First-Line Treatment.
Marcelo CorassaRodrigo Fonseca AbreuVladmir Cláudio Cordeiro de LimaGiovana Tardin TorrezanFelicia Peterson CavalherTullio Novaes SilvaThiago Bueno de OliveiraHelano Carioca FreitasDirce Maria CarraroFelipe D'Almeida CostaPublished in: JCO precision oncology (2022)